Dr. Nathan N. Levitan MD

Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy

Afshin Dowlati, S. Subbiah, Matthew M. Cooney, Kimberly Rutherford, Tarek Mekhail, Pingfu Fu, Robert Chapman, A. Ness, Tania Cortas, Joel N. Saltzman, Nathan Levitan, Gregory Warren

Randomized phase II trial of different schedules of administration of rebeccamycin analogue as second line therapy in non-small cell lung cancer.

Afshin Dowlati, Robert Chapman, S. Subbiah, Pingfu Fu, A. Ness, Tania Cortas, Lauren Patrick, Sherrie Reynolds, Natalie Xu, Nathan Levitan, Percy Ivy, Scot C. Remick

Combination chemotherapy with topotecan for non-small cell lung cancer

Afshin Dowlati, Nathan Levitan

Correlation of EUS measurement with pathologic assessment of neoadjuvant therapy response in esophageal carcinoma

Joseph Willis, Gregory S. Cooper, Gerard Isenberg, Michael V. Sivak, Nathan Levitan, Julie Clayman, Amitabh Chak

Paclitaxel added to the cisplatin/etoposide regimen in extensive-stage small cell lung cancer -- the use of complete response rate as the primary endpoint in phase II trials.

Afshin Dowlati, Lori Crosby, Scot C. Remick, Vinit Makkar, Nathan Levitan

Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer

Afshin Dowlati, Nathan Levitan, Nahida H. Gordon, Charles L. Hoppel, David M. Gosky, Scot C. Remick, Stephen T. Ingalls, Sossamma J. Berger, Nathan A. Berger

Endosonographic assessment of multimodality therapy predicts survival of esophageal carcinoma patients

Amitabh Chak, Marcia I. Canto, Gregory S. Cooper, Gerard Isenberg, Joseph Willis, Nathan Levitan, Julie Clayman, Arlene Forastiere, Elisabeth Heath, Michael V. Sivak

Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiation

Gerard Isenberg, Amitabh Chak, Marcia I. Canto, Nathan Levitan, Julie A. Clayman, BJ Pollack, Michael V. Sivak